This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Nephros Inc. (NEPH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 14.29% and 6.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0.00% and 0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Nephros Inc. (NEPH) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Could Help Nephros Inc. (NEPH) Maintain Its Recent Price Strength
by Zacks Equity Research
Nephros Inc. (NEPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Nephros Inc. (NEPH) a Good Fit for "Trend Investing"
by Zacks Equity Research
Nephros Inc. (NEPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Nephros Inc. (NEPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 57.14% and 1.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 33.33% and 1.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nephros Inc. (NEPH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for August 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Chembio (CEMI) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Chembio (CEMI) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Nephros Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Nephros has been struggling lately, but the selling pressure may be coming to an end soon.
OraSure Technologies (OSUR) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
OraSure Technologies (OSUR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Abbott (ABT) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Abbott (ABT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Agios' IND for PKR Activator AG-946 Gets FDA Clearance
by Zacks Equity Research
The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
Nephros Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Nephros has been struggling lately, but the selling pressure may be coming to an end soon.
Top Ranked Momentum Stocks to Buy for October 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 23rd